Structure and function of L-threonine-3-dehydrogenase from the parasitic protozoan Trypanosoma brucei revealed by X-ray crystallography and geometric simulations by Adjogatse, Eyram et al.
        
Citation for published version:
Adjogatse, E, Erskine, P, Wells, SA, Kelly, JM, Wilden, JD, Chan, AWE, Selwood, D, Coker, A, Wood, S &
Cooper, JB 2018, 'Structure and function of L-threonine-3-dehydrogenase from the parasitic protozoan
Trypanosoma brucei revealed by X-ray crystallography and geometric simulations', Acta Crystallographica
Section D: Structural Biology, vol. 74, no. 9, pp. 861-876. https://doi.org/10.1107/S2059798318009208
DOI:
10.1107/S2059798318009208
Publication date:
2018
Document Version
Peer reviewed version
Link to publication
The final published version is available at IUCr via https://doi.org/10.1107/S2059798318009208.
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019
1 
 
Structure and function of L-threonine-3-dehydrogenase from the 
parasitic protozoan Trypanosoma brucei revealed by X-ray 
crystallography and geometric simulations 
Eyram Adjogatse*a, Peter Erskinea, Stephen Wellsb, John M Kellyc, Jonathan D Wildend, A. W. Edith 
Chane, David Selwoode, Alun Cokera, Steve Wooda, Jonathan B. Coopera 
 
*Corresponding Author (rmhaead@ucl.ac.uk) 
aLaboratory for Protein Crystallography, Wolfson Institute for Biomedical Research, University 
College London, London, WC1E 6BT, United Kingdom 
bDepartment of Chemistry, University of Bath, Bath, BA2 7AY, United Kingdom 
cDepartment of Pathogen Molecular Biology, London School of Hygiene & Tropical Medicine, 
London, WC1E 7HT, United Kingdom 
dDepartment of Chemistry, University College London, London, WC1H OAJ, United Kingdom 
eDrug Discovery, Wolfson Institute for Biomedical Research, University College London, London, 
WC1E 6BT, United Kingdom 
2 
 
Abstract 
Two of the world’s most neglected tropical diseases, human African trypanosomiasis (HAT) and 
Chagas Disease, are caused by protozoan parasites of the genus Trypanosoma. These organisms 
possess specialised metabolic pathways, frequently distinct from those in humans, which have 
potential to be exploited as novel drug targets. This study elucidates the structure and function of L-
threonine-3-dehydrogenase (TDH) from T. brucei, the causative pathogen of HAT.  TDH is a key 
enzyme in the metabolism of L-threonine, and a TDH inhibitor has been shown to have trypanocidal 
activity in the procyclic form of T. brucei.  TDH in humans is a non-functional pseudogene, suggesting 
that it may be possible to rationally design safe and specific therapies for trypanosomiasis by 
targeting this parasite enzyme.  As an initial step, the TDH gene from T. brucei has been expressed, 
and the three-dimensional structure of the enzyme has been solved by X-ray crystallography.  In 
multiple crystallographic structures, T. brucei TDH is revealed to be a dimeric short-chain 
dehydrogenase that displays a considerable degree of conformational variation in its ligand binding 
regions.  Geometric simulations of the structure have provided insight into the dynamic behaviour of 
this enzyme. Furthermore, the structures of TDH bound to its natural substrates and known-
inhibitors have been determined, giving an indication of the mechanism of catalysis of the enzyme.  
Collectively, these results provide vital details for future drug design to target TDH or related 
enzymes. 
 
Synopsis 
Relationships between the structure and function of a putative drug target for human African 
trypanosomiasis are elucidated using X-ray crystallography and Geometric Simulations.  The data 
presented provide insight into ligand binding and catalysis, giving direction to future rational drug 
design. 
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1. Introduction 
Trypanosomiasis is a human and animal disease caused by infection with insect-transmitted parasites of the genus Trypanosoma, protozoa distinguished by 
a single flagellum.  In humans, Trypanosoma brucei causes human African trypanosomiasis (HAT), which is endemic in sub-Saharan Africa, and Trypanosoma 
cruzi causes Chagas disease, which is widespread in South America.  HAT is fatal if left untreated, whilst Chagas disease often results in chronic and life-
threatening pathology many years after the initial infection (Büscher et al., 2017; Bern, 2015). 
Both HAT and Chagas disease have been designated as Neglected Tropical Diseases (NTDs).  These debilitating infections often affect poorer populations 
within developing countries, and have historically received less attention for pharmaceutical R&D. As a result, there are a limited number of drugs available 
for both diseases, and these have numerous shortcomings, which include toxicity, limited efficacy, and acquisition of resistance by the pathogens.  
Developing a more detailed understanding of Trypanosoma biochemistry and metabolism should aid the identification of new drug targets.  
The main hypothesis of this project is that a genetic difference between trypanosomes and their human hosts is exploitable for drug design. It is known that 
the insect gut form of T. brucei selectively and rapidly metabolises L-threonine by the action of L-threonine 3-dehydrogenase (TDH). Indeed, inhibitors of 
TDH have been shown to be lethal to the procyclic form of the parasite (Cross et al., 1975; Linstead et al., 1977). More recent work has shown that TDH is a 
pseudogene and non-functional in humans, and that an alternative metabolic pathway exists (Edgar, 2002). This suggests that inhibitors of trypanosome 
TDH may have potential as highly specific anti-parasitic agents. Recent work using reverse genetics has shown that glucose and threonine contribute almost 
equally to Ac-CoA production, both being crucial in bloodstream form (BSF) and procyclic form parasites, with concomitant blockade of the corresponding 
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pathways inducing cell death (Millerioux et al., 2013; Mazet et al., 2013). Hence, we expressed and crystallised T. brucei TDH, and derived its crystal 
structure at high resolution with various physiological ligands bound.  
 
There are three known pathways of threonine catabolism, which are initiated by L-threonine aldolase (EC 4.1.2.5), L-threonine dehydratase (also known as 
L-threonine deaminase; EC 4.2.1.16) and L-threonine 3-dehydrogenase (TDH; EC 1.1.1.103)., which is the dominant pathway in several prokaryotes and 
eukaryotes (Bowyer et al., 2009; Marcus & Dekker, 1993b; Edgar, 2002).  The activity of L-threonine aldolase has been shown to be low or insignificant in 
prokaryotes (Lam et al., 1980) and eukaryotes (Bird & Nunn, 1983) and no expression of the enzyme has been detected in humans (Edgar, 2005).  In 
contrast, the pathway initiated by L-threonine dehydratase is a major mechanism for L-threonine catabolism and can become the dominant pathway in 
certain metabolic states in animals (Bird & Nunn, 1983).  The other major route for L-threonine catabolism is initiated by the mitochondrial matrix enzyme 
TDH, and appears to be the dominant pathway in many prokaryotes and eukaryotes (Bowyer et al., 2009; Marcus & Dekker, 1993b; Edgar, 2002).  In this 
pathway, TDH works in tandem with a second enzyme, 2-amino-3-ketobutyrate ligase (KBL) to catabolise L-threonine to glycine and Ac-CoA (Error! 
Reference source not found.). 
 
In the first part of this process, TDH oxidises L-threonine to 2-amino-3-ketobutyrate (AKB) in a reaction dependent on NAD(H).  There is evidence that AKB is 
unstable and spontaneously breaks down to aminoacetone and carbon dioxide.  Thus it has been suggested, and backed by other evidence,  that TDH and 
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KBL form a multi-enzyme complex to facilitate the completion of the second reaction, the breakdown of AKB to Ac-CoA and glycine by KBL (Dale, 1978; 
Bowyer et al., 2009). 
 
TDH belongs to an enzyme family that is sub-divided into short-chain (SDR), medium-chain (MDR) and long-chain (LDR) dehydrogenase/reductases 
(Kavanagh et al., 2008).  Several of the most studied TDHs have been MDRs, showing a tetrameric quaternary structure and a requirement for divalent 
metal cations, such as zinc (Boylan & Dekker, 1978, 1981; Bowyer et al., 2009; Higashi et al., 2005; Ishikawa et al., 2007; Machielsen & van der Oost, 2006).  
More recently, a second group of TDH enzymes that share features with UDP-galactose 4’-epimerase (UDP-GalE) have been characterised.  These enzymes 
belong to the SDR family, and in contrast to the MDR TDH enzymes, they are dimeric and have no requirement for divalent cations (Yoneda et al., 2010, 
2012; Ueatrongchit & Asano, 2011).  KBL has not been studied to the same extent, but the crystallographic structure of the enzyme from Escherichia coli has 
been published (Schmidt et al., 2001). 
 
The L-threonine degradation pathway catalysed by TDH and KBL plays a variety of roles in both prokaryotes and eukaryotes, including energy production, 
homeostasis and fatty acid synthesis.  The pathway and its constituent enzymes have been studied in T. brucei, but crystal structures of the enzymes are yet 
to be published. 
T. brucei was shown by Cross et al. to preferentially and exhaustively consume L-threonine when grown in mixed media (Cross et al., 1975).  Furthermore, it 
was shown that most of the absorbed threonine was catabolised via the TDH pathway, producing Ac-CoA and glycine.  To further underline the importance 
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of this pathway, exposure of cultured T. brucei to tetraethyl thiuram disulphide (TETD, marketed as Antabuse), an inhibitor of human aldehyde 
dehydrogenase and a potent inhibitor of TDH, has been demonstrated to lead to trypanosome death in correlation with the degree of TDH inhibition (Cross 
et al., 1975; Linstead et al., 1977).   
A principal reason for the detrimental effect of TDH inhibition on T. brucei is the importance of the pathway for fatty acid synthesis, for which Ac-CoA is a 
substrate.  Millerioux, Mazet and colleagues have demonstrated that Ac-CoA is required for fatty acid synthesis by simultaneously inhibiting TDH and 
another key Ac-CoA-producing enzyme, pyruvate dehydrogenase, which proved to be lethal for the parasite (Millerioux et al., 2013; Mazet et al., 2013).  
The physiological role of L-threonine metabolism through the TDH pathway is not limited to fatty acid production and there may be additional functions not 
yet elucidated.  For instance, glycine produced from L-threonine by TDH in T. brucei has been shown to be incorporated into trypanothione (Millerioux et 
al., 2013), an antioxidant analogous to glutathione found in humans.  In addition, studies of 13C-labelled glucose metabolism in BSF T. brucei showed that 
glucose-derived acetate was used to acetylate amino acids, and it was suggested that L-threonine-derived acetate plays a role in this process (Creek et al., 
2015).  
 
Below, we present the first complete description of the tertiary and quaternary structure of TbTDH, as analysed by X-ray crystallography and a range of 
other biochemical and computational techniques. The results give insight into the relationship between TDH and its natural cofactor and substrate, and also 
the relationship between TDH and the subsequent enzyme in the pathway, KBL. 
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2. Materials and Methods 
2.1. Expression and Purification 
The genes for TDH and KBL were amplified by PCR from T. brucei genomic DNA and cloned into the NdeI and BamHI sites of the E. coli expression vector 
pET15b using standard methods and then expressed in E. coli. The protein was then purified from the supernatant solutions extracted from cell lysates 
using nickel affinity chromatography, employing a HisTrap HP column (GE Healthcare) to isolate His-tagged protein.  Purity of protein solutions was 
determined by SDS-PAGE and by size-exclusion chromatography (SEC).  SEC was performed on a Superdex 200 10/300 GL column (GE Healthcare), testing 
200-400μl samples using Fast Performance Liquid Chromatography (FPLC) (Pharmacia Biotech) at a flow rate of 0.5ml/min and a maximum pressure of 1.5 
MPa. Before any experimental samples were run, the column was calibrated according to the manufacturer’s instructions with the standards.  Protein 
elution volumes (Ve) were determined by following UV absorbance at 280 nm (A280).  The void volume (Vo) of the column was determined by running a 
sample of Blue dextran (MW 2000 kDa), which is not retained by the resin, due to its size.  TDH and KBL were identified by using a standard calibration 
curve to predict the molecular weights of proteins eluting at a particular elution volume, with confirmation by SDS-PAGE. 
Where it was desired to improve the purity of the protein solutions after affinity chromatography, ion-exchange chromatography (IEC) was employed.  
Appropriate conditions for IEC were determined by using the ProtParam tool on the ExPASy server to predict the isoelectric points of TDH and KBL from 
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their amino acid sequences. IEC was performed on a 250ml Q-sepharose column using an ÄKTA Prime (GE Healthcare) FPLC machine.  Protein was purified 
by eluting with a gradient of 1000ml solvent progressing from low salt buffer (100 mM NaCl) to high salt buffer (1 M NaCl). 
TDH and KBL solutions were stored in ice baths and refrigerated at 2-8°C.  The proteins could be stored in this way for at least one month without an 
appreciable loss in function.  Alternatively, solutions were stored for longer periods, frozen at -20°C, and loss of function was not observed after several 
months of freezing the proteins. 
 
2.2 .X-ray crystallography 
2.2.1. Crystallisation 
Proteins were crystallised by use of the hanging drop method, using commercial crystallisation screens or manually prepared solutions.  All details are 
provided in Table 1. 
To prepare co-crystals of the proteins with ligands, two methods were attempted: substrates, inhibitors and metal ions were incorporated into the 
crystallisation solution and protein-ligand complexes were co-crystallised using the method described above, or alternatively, crystals were soaked in 
solutions containing additional substances of interest for periods of 5 minutes to 1 hour. Only the first co-crystallisation method yielded co-crystals of 
ligand-bound protein. 
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Prior to data collection, crystals were harvested using a fabric or plastic loop and cryo-cooled by one of three methods: the loop and crystal were plunged 
directly into a bath of liquid nitrogen, the loop and crystal were suddenly exposed to a stream of cryo-cooled nitrogen gas or the loop and crystal were 
plunged into liquid ethane for one second and then into liquid nitrogen.  As cryo-cooling presents the risk of causing damage to crystals, cryoprotectants 
such as glycerol, ethylene glycol or PEG 400 were sometimes added.  In these cases, crystals were transferred to a 10 µl drop of crystallisation well solution 
and four 1 µl drops of cryoprotectant were sequentially mixed into this solution before the crystal was cryo-cooled as described above. 
 
X-ray data were collected at synchrotron radiation sources, the European Synchrotron Radiation Facility (ESRF) and Diamond Light Source (DLS). Early data 
processing was either carried out manually or by use of the integrated data reduction pipeline, xia2 (Winter, 2010), at DLS.  When early data processing was 
carried out manually, data integration was carried out using iMosflm (Battye et al., 2011). When automated processing was carried out by xia2, the 
program XDS (Kabsch, 2010) was used.  Space group determination was initially attempted by selecting from iMosflm-provided options, or it was carried 
out automatically using POINTLESS (Evans, 2005, 2011). Scaling and merging were carried out using Scala (Evans, 2005) or Aimless (Evans & Murshudov, 
2013), together with ctruncate (Stein & Ballard, 2009) to convert the intensities into structure factors. As an analogous TDH structure was already available 
in the PDB, phase determination for all TDH structures described herein was carried out by means of molecular replacement, using Molrep (Vagin & 
Teplyakov, 1997, 2009) or Phaser (McCoy et al., 2007).  In order to determine the appropriate number of molecules per asymmetric unit, Matthews_coef 
(Kantardjieff & Rupp, 2003) was used. Refinement was performed using Refmac5 (Murshudov et al., 1997; Vagin et al., 2004). To incorporate ligands into 
the model, their structures were produced as .pdb files, along with restraints (stored in .cif files, used by Refmac), using the online ProDRG server 
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(Schüttelkopf & van Aalten, 2004).  Once positioned correctly, in accordance with its associated electron density, ligand files were merged with protein .pdb 
files. 
The structure visualisation and manipulation software, Coot (Emsley & Cowtan, 2004; Emsley et al., 2010), was used on Windows and Linux systems to carry 
out real space refinement and validation of structures. Manipulation of structures was guided by 2Fo-Fc maps at σ levels of 1.5 and by Fo-Fc maps at σ 
levels of 2.00.  Similarly, solvent molecules were identified by placing them within unoccupied volumes of electron density and retaining molecules with 
accurate fits to the electron density after refinement. 
To validate models, bond distances and geometries, including those in hydrogen bonding networks, were observed visually and modified accordingly. The 
Ramachandran plot function in Coot was used to find and correct errors in the phi (φ) and psi (ψ) angles of amino acid residues.  Coot’s rotamer analysis 
tool was also used to correct side chain orientations in TDH structures. 
 
2.3 Structural Analysis 
2.3.1. Sequence Analysis 
Nucleotide and amino acid sequences from TbTDH (Uniprot Q7YW97) were compared with those of TDH from other organisms using the National Center 
for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul et al., 1990).  Certain evolutionarily conserved sequences were 
also identified in the 2D sequences and visually using Coot and other visualisation software, such as UCSF Chimera (Pettersen et al., 2004). 
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2.3.2. 3D structure 
Protein structure models and their interactions with ligands were observed visually using PyMOL (Schrödinger LLC), Coot and UCSF Chimera (Pettersen et 
al., 2004). To analyse conformational variability evident in various TbTDH structures, eight representative monomers from solved structures were compared 
in a method similar to Huntington (Huntington, 2008). The CCP4 program baverage was used to calculate average B-factors per residue for all main chain 
atoms.  UCSF Chimera was used to visualise the mean B-factors and the RMSDs calculated between α-carbons of the eight structures when superimposed.  
The program PISA (Protein Interfaces, Surfaces and Assemblies) (Krissinel & Henrick, 2007) in the CCP4 package was used to output the quaternary 
structures of TDH models for further analysis.  
2.3.3. Geometric simulations of flexible motion 
Amplitudes of motion in models of TDH were simulated using a combination of rigidity analysis and coarse-grained elastic network normal mode analysis, as 
described previously (Jimenez-Roldan et al., 2012; Wells et al., 2015). Elnemo software was used (Suhre & Sanejouand, 2004) to obtain normal mode 
eigenvectors from coarse-grained elastic network modelling, and FIRST/FRODA software (Jacobs et al., 2001; Wells et al., 2005) to carry out rigidity analysis 
(FIRST) (Hespenheide et al., 2002), identifying the noncovalent interaction network and labelling dihedral angles as locked or variable, and template-based 
geometric simulations of flexible motion (FRODA) (Wells et al., 2005) which project the all-atom structure over large amplitudes of motion while 
maintaining local bonding and steric geometry. 
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Normal mode eigenvectors were generated in Elnemo in a one-site-per-residue coarse-graining using the Cα geometry of the input structure, placing 
springs of equal spring constant between all sites lying within an interaction distance cut-off of 12 Å.  A rigidity analysis of the all-atom input structure was 
carried out in FIRST using the "pebble game" algorithm (Jacobs et al., 2001; Jacobs & Thorpe, 1995) which matches degrees of freedom against bonding 
constraints in the molecular framework of the protein. Bonding constraints include covalent, hydrophobic and polar (hydrogen bond and salt bridge) 
interactions. As the strength of the polar interactions can be gauged from their geometry, the results of the analysis depend on an "energy cut-off" which 
selects the set of polar interactions to include in the constraint network (Hespenheide et al., 2002). A cut-off of -2.0 kcal/mol was used in this study. 
Template-based geometric simulation of flexible motion, carried out using FRODA, explores the mobility of the all-atom structure by iterative perturbation 
and relaxation of atomic positions in parallel and antiparallel to the direction of normal-mode eigenvectors. Several thousand iteration steps are carried out 
to generate large motion amplitudes. The simulation generates an initial phase of "easy" motion, where the bonding geometry is easily maintained, 
followed by the onset of "jamming" as the motion encounters steric and bonding constraints which naturally limit its amplitude. The conformational 
changes of geometric simulations of TDH projected using this method were observed and compared with superpositions of crystallographic models in 
PyMOL and UCSF Chimera. 
2.4. Other biochemical techniques 
2.4.1. Size-exclusion chromatography 
SEC was used as described above to determine the oligomeric states of TDH and KBL.  Before any experimental samples were run, the column was 
calibrated with the standards: β-amylase (MW 200 kDa), alcohol dehydrogenase (MW 150 kDa), bovine serum albumin (BSA) (dimer MW 132 kDa; 
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monomer MW 66 kDa), ovalbumin (MW 45 kDa), carbonic anhydrase (MW 24 kDa) and cytochrome C (12.4 kDa).  To estimate the molecular weights of 
proteins eluting at a particular elution volume (Ve), a plot of log10 molecular weight of standard protein against the elution volume: void volume ratio (Ve/V0) 
was made using Microsoft Excel. A number of experiments testing TDH and KBL in isolation, together and in the presence of substrates were carried out to 
measure changes in the observed elution volumes and oligomeric states predicted by linear regression analysis. 
2.4.2. Cross-linking 
Cross-linking studies of TDH and KBL were carried out using a method similar to that of Davies and Stark (Davies & Stark, 1970), which employed dimethyl 
suberimidate (DMS) as the cross-linking agent. As cross-linking reactions predominate within oligomers, this was used to provide an indication of the 
oligomeric states of TDH and KBL. Protein concentrations and DMS concentrations were carefully chosen to avoid precipitation.  
All solutions were made up to 50μl or 100μl in 200mM Tris.HCl buffer at pH 8.5. Final protein concentrations were approximately 1mg/ml. Reactions were 
carried out in duplicate, at room temperature and at 2-8°C. The samples were incubated for 3 hours or overnight and the reactions were then halted by the 
addition of Laemmli buffer in preparation for analysis by SDS-PAGE. Gels of 9% polyacrylamide, rather than the usual 12%, were used to increase the 
migration of higher molecular weight complexes. 
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3. Results 
3.1. Structure of TDH 
3.1.1. Crystal growth and Data Collection 
Diffracting TDH crystals were successfully grown under several different conditions, which are listed in Table 1, and data collection and refinement statistics 
for the related data sets are listed in Table 2. Diffracting TDH crystals were cryo-cooled using glycerol, PEG 400 or ethylene glycol.  It was also possible to 
collect quality data from crystals cooled in the absence of cryoprotectant, as exemplified by the data used to solve two structures (PDB: 5K4W and PDB: 
5K4Y).   
3.1.2. TbTDH primary and secondary structure 
TDH primary sequence alignments showed that the TDH enzymes from T. brucei strain TREU 927 and T. brucei gambiense are essentially identical, 
confirming that the TDH studied in this work is relevant to a human pathogen. The animal pathogen T. congolense has a protein that shares 78% sequence 
identity with the TDH studied here. The sequence identity between TDH from T. brucei strain TREU 927 and the Chagas disease-causing pathogen, 
Trypanosoma cruzi, is 72%. Thus, TDH from a range of Trypanosoma species are closely related (Supplementary Figure 1). 
Other TDH enzymes with a high sequence similarity to TbTDH include the UDP-galactose 4’-epimerase-like (GalE) TDH enzymes from Thermoplasma 
volcanium, Flavobacterium frigidimaris and Cupriavidus necator. The corresponding enzymes from these organisms have monomeric molecular weights 
between 35 and 37.2kDa, matching that of TDH from T. brucei (37.8 kDa). Another group of related TDH enzymes originate from mammalian and avian 
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species: Rattus norvegicus (rat), Sus scrofa (boar/pig), Capra hircus (goat) and Gallus gallus (red junglefowl). TDH enzymes from these species have been 
studied previously and shown to have molecular weights in the range of 36 kDa (Yuan & Austic, 2001) to 37 kDa (Kao & Davis, 1994). 
Inspection of the sequences of the various TDHs shows that they belong to the SDR superfamily of enzymes. Two highly conserved structural features that 
can be identified from the sequence are highlighted in Supplementary Figure 2. The first, a glycine-rich region, is represented by the sequence GxxGxxG, 
and the second consists of a tyrosine and a lysine residue separated by three other residues: YxxxK. 
The X-ray structures of TbTDH reported here revealed that each individual subunit consists of two domains displaying α/β topology. The distribution of 
secondary structure elements in TDH appears to be approximately 46% α-helix and 15% β-sheet. 
 
3.1.3. TbTDH tertiary structure 
TbTDH encompasses an NAD-binding domain, which includes the first 180-200 amino acids, and a catalytic domain at the C-terminal end of the protein 
(Supplementary Figure 3). In three dimensions, there is some crossover between these domains. In the N-terminal domain there is a Rossmann fold motif 
(parallel β-strands flanked by α-helices), which is characteristic of NAD-binding proteins, and hence SDRs.  The structural motif GxxGxxG, which is common 
to the ‘extended’ class of SDRs (eSDR), is located within the NAD binding region and is represented by the sequence Gly9-Ala10-Leu11-Gly12-Gln13-Ile14-
Gly15. This motif is involved in binding the diphosphate group of NAD. The YxxxK motif and several other conserved residues, including Met81, Ser82, 
Thr119, Thr186, Trp280, and Tyr144 and Lys148 of the SDR YxxxK motif are located in the active site. 
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When comparing the different crystallographic models, which were obtained with different ligands and crystallised in different space groups, no large 
domain movements were observed.  An analysis of the average B-factor for each residue revealed the presence of high B-factors for some residues, 
supporting the notion that those regions of the protein are more disordered than others, and thus more flexible.  
A number of regions in TbTDH appear to be flexible (Error! Reference source not found.). Firstly, there are two disordered loop regions: Loop 1 includes 
residues Thr179 and Ala185, and Loop 2 lies between residues Asp35 and Asn60. There also appears to be a higher degree of flexibility in the catalytic 
domain (gold and red-coloured region on the right-hand side of Error! Reference source not found.a). The most striking evidence of conformational 
variability is found in the residues of Loop 1. Indeed, in different crystallographic structures, this loop was found to occupy two distinctive positions: one 
where the loop was in an ‘open’ position, lying at a distance of approximately 5 Å from the active site, and another where the loop was ‘closed’ and 
positioned adjacent to the active site (Error! Reference source not found.). Therefore, for each model of a TDH monomer, the structure can be classified as 
‘open’ or ‘closed’, on the basis of the conformation of Loop 1.  Comparing the average B-factors in the open and closed structures highlighted changes in 
flexibility or disorder that accompanied the change in the Loop 1 conformation. For example, Figure 4b shows the average B-factors of TDH residues in 
‘open’ structures, whilst Figure 4c shows the average B-factors for the ‘closed’ structures. 
In the ‘open’ structures, the highest B-factors are seen around both loop regions. However, in the closed structures, although these same residues have 
above average B-factors, they are much less disordered. Inspection of Error! Reference source not found.c demonstrates that the catalytic domain appears 
to be more disordered in closed structures. In three dimensions, this region can be seen as one of a pair of adjacent α-helices and β-strands, which are the 
gold-coloured regions on the right hand sides of the structures in Error! Reference source not found.a and Error! Reference source not found.a. 
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The NAD-binding region, particularly around Loop 2, also appears to be flexible. Although the B-factors are low, the RMSDs around residues 82 to 100 are 
particularly high (Error! Reference source not found.b). This region lies at the dimerization interface (discussed below), indicating some conformational 
variability there.   
These findings indicate that there may be a relationship between the conformation of Loop 1, and the flexibility of other regions of the protein, particularly 
the catalytic domain. Although a variety of different crystallisation conditions were used, the different conformational changes do not appear to correlate 
with the composition of the crystallisation mixture, the use of a cryoprotectant or the space-group of the crystal ( 
 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Crystallisation Conditions          
Conditions 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]) 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]); 
NAD+ 
(1mM); 
pyruvate 
(30mM) 
0.2M lithium 
sulphate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (6.4 x 
10-2mM 
[2.4mg/ml]); 
KBL (3.8 x 
10-2mM 
[1.8mg/ml]); 
NAD+ 
(0.09mM); 
PLP 
(0.18mM);  
L-Threonine 
(7.33mM) 
0.1M MES; 
0.2M 
ammonium 
sulphate; 
30% w/v 
PEG 5K 
MME; pH 
6.5; 
TDH (9.0 x 
10-2mM 
[3.4mg/ml]);  
L-serine 
(50mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
8.5;  
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
BPOB 
(0.5mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(8.5mM); 
quinine 
(2.5mM 
[hydrochlorid
e 
dehydrate]) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (10.4 x 
10-2mM 
[3.9mg/ml]); 
NAD+ 
(10mM); L-
allo-
threonine 
(30mM) 
0.2M sodium 
acetate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (9.3 x 
10-2mM 
[3.5mg/ml]); 
NADH 
(10mM);  
L-Threonine 
(30mM) 
0.1M tri-
sodium 
citrate; 25% 
w/v PEG 
4K; 0.2M 
ammonium 
acetate; pH 
5.6 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
methylglyox
al (8mM) 
Cryoprotectant Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol None None 
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Table 2 and Table 2). Thus, the specific conformation of Loop 1 and the flexibility of the catalytic 
region may actually be influenced by ligand binding. Indeed, three of the four ‘closed’ structures 
(from PDB: 5K4U, PDB: 5K4W and PDB: 5K50) examined were bound to NAD/NADH and another 
ligand, whilst only one of the four ‘open’ structures (from PDB: 5K50) examined possessed bound 
NAD and another ligand. Despite the evident changes in disorder that may be associated with ligand 
binding and catalysis, the crystallographic structures did not capture any significant changes in the 
relative positions of residues important in NAD and L-threonine binding. 
 
3.1.4. TbTDH quaternary structure and complex formation 
TDH was shown to exist as a dimer following refinement of all the X-ray crystallographic models. The 
dimerization interface covers a surface area of approximately 1200-1300 Å2 and consists of two α-
helices (Pro89-Tyr110 and Val143-Tyr162) and a loop (Lys126-Thr142), with the same regions on 
each monomer making contact in the dimer. As can be seen in Error! Reference source not found., 
the dimer is stabilised by a large number of hydrophobic, polar and ionic interactions. In particular, 
polar side chains of residues on each monomer form hydrogen bonds with each other and charged 
residues form salt bridges. Interactions across this interface include the following: Glu86 with 
Trp157; Asp90 with Arg101; Asp94 with Arg101; Lys126 with Asp135. This probably gives greater 
stability to the dimer, whilst the length of some of the side chains allows their interactions to be 
maintained in the case of any change in the orientation of the two monomers. 
Further evidence of the existence of the dimer and that this is the largest oligomer present in all of 
the crystallographic structures, was provided using the software PISA (Krissinel & Henrick, 2007).  
Supplementary Table 1 lists a number of different interfaces between different TDH subunits in the 
different structural models and it can be seen that the only stable association predicted by PISA is 
the dimer relationship previously described. There is no clear relationship between the crystal space 
group and the nature of the dimerisation interface. 
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3.2. Oligomerisation studies 
The cross-linking studies carried out using dimethyl suberimidate (DMS) provide more evidence in 
regard to the oligomeric states of TDH, and the subsequent enzyme in this threonine degradative 
pathway, KBL.  SDS-PAGE analysis of the samples revealed protein bands representing monomeric 
and dimeric forms of TDH and KBL (Supplementary Figures 6-8).  A single two-fold dilution of the 
concentration did not have an effect on the apparent oligomeric states detected by the cross-linking 
experiments.  Experiments conducted with TDH and KBL together do not suggest that the two 
proteins are complexed in solution, as there are no additional bands present (Supplementary Figure 
6, lanes 7 and 8), compared to when samples of the two proteins were tested separately 
(Supplementary Figure 6, lanes 1, 2, 4 and 5). The pull-down assay using His-tagged KBL and native 
TDH was in agreement with the data from the cross-linking studies, suggesting that TDH and KBL do 
not appear to form a complex with each other in solution. When His-tagged KBL was applied to the 
Ni-NTA column, non-tagged TDH washed through with the wash buffer. Meanwhile, KBL was 
retained on the column, and elution with the 250mM imidazole elution buffer caused KBL to elute 
alone, demonstrating that the two proteins had not bound to each other under the conditions 
tested (Supplementary Figure 9). 
 
Size-exclusion chromatography experiments (SEC) experiments initially reinforced the results 
described thus far: when assayed separately, elution volumes of TDH and KBL indicated that they 
exist in dimeric forms in solution (Supplementary Table 2). The TDH results were therefore 
consistent with the findings gained by X-ray crystallography.  Interestingly, when mixed and assayed 
together, TDH and KBL co-eluted predominantly at a volume suggesting the existence of the proteins 
as monomers. Miniscule amounts of both proteins eluted at a volume corresponding to a large 
oligomer of approximately 188 kDa , but the low protein concentrations make this observation 
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inconclusive. Overall, the SEC findings confirm the dimeric structure of TDH. Additionally, an 
indication of potential interactions between TDH and KBL was obtained, however further study is 
required to confirm the dissociation of TDH and KBL dimers or the existence of a TDH:KBL complex. 
 
 
3.3. Structural insights into ligand binding and catalysis 
To gain a complete picture of the TDH structure as it relates to function, various ligands, including 
the natural substrates, were co-crystallised with TDH prior to obtaining diffraction data.  
Crystallographic models containing NAD(H), L-threonine, L-allothreonine and pyruvate, were all 
solved with those ligands at an occupancy of 1. As can be seen in Error! Reference source not found. 
and Error! Reference source not found., the TDH substrates, NAD+ and L-threonine, occupy a deep 
cleft in the protein. The L-threonine binding pocket and the pocket occupied by the nicotinamide 
group of NAD+ are partially separated by the side chain of Met81 (Figure 7). 
NAD binds TDH through a combination of hydrogen bonds and hydrophobic interactions with several 
main chain and side chain atoms of TDH residues. The interactions with important TDH residues are 
displayed in Error! Reference source not found.b. In addition, the cofactor also hydrogen-bonds 
with several water molecules. This is particularly the case for the phosphate groups, the ribose 
hydroxyl groups and the nicotinamide amide (Error! Reference source not found.a). Three-
dimensional analysis shows that NAD’s nicotinamide and the adjacent ribose groups bind in deep 
pockets of the protein, whilst the remainder of the NAD molecule faces the exterior. Additionally, 
unoccupied pockets can be observed adjacent to the nicotinamide amide and C2 of the adenine ring 
(see Supplementary Figure 10), suggesting molecules of a different size and shape could be 
accommodated into the same binding site.  
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To gain insight into L-threonine binding, TDH was co-crystallised with it and the reduced form of the 
cofactor (NADH) to prevent turnover, which involves oxidation of the amino acid.  The L-threonine-
bound structure (PDB: 5K4W) at 1.72 Å resolution (Error! Reference source not found.) reveals that 
the carboxyl group of L-threonine hydrogen-bonds with the side chain and main chain atoms of 
Ser82 and Thr186. The amine group of L-threonine is seen to hydrogen-bond with the side chain 
hydroxyl group of Thr186, with the nicotinamide carbonyl of NADH and with a nearby water 
molecule. The side chain hydroxyl group of L-threonine is hydrogen-bonded to Thr119 and Tyr144, 
whilst the methyl group is directed towards the hydrophobic amino acid Trp280. This aligns the β-
carbon with the C4 atom of the nicotinamide ring (discussed in more detail below). Another 
interesting feature of this structure was that the flexible loop, Loop 1, is closed over the active site, 
meaning that it is completely shielded by the enzyme (Error! Reference source not found.c). This 
was the case in both TDH monomers in the asymmetric unit of the structure, both of which were 
bound to NADH and L-threonine. 
X-ray crystallographic structures of TDH bound to compounds reported to be inhibitors, L-allo-
threonine (Klein et al., 1980) and pyruvate (Kazuoka et al., 2003; Yoneda et al., 2012), were also 
successfully solved.  These compounds were shown to occupy the L-threonine binding site, forming 
interactions with some of the same active site residues as the natural TDH substrate, thereby 
demonstrating their modes of inhibition (Supplementary Figure 11). 
The putative mechanism of reaction of TDH involves transfer of a hydride from the β-carbon of L-
threonine to the C4 atom of the nicotinamide ring (Yoneda et al., 2010). The data presented here 
confirm that the atoms involved in this reaction are well aligned and at a distance that would permit 
such a reaction to happen (Error! Reference source not found.).  X-ray structures described herein 
confirmed the presence and interaction of key putative catalytic residues, such as Thr119, Tyr144 
and Thr186 (Figure 7).  Another structural feature that is conserved in SDRs and deemed important 
for catalysis is a chain of water molecules that is believed to form a proton relay that transfers the 
23 
 
proton extracted from L-threonine to the bulk solution, allowing the enzyme to catalyse another 
reaction. This water chain requires a certain orientation of residues to bind the water molecules. The 
feature observed in several SDRs is an interaction between an asparagine side chain and the main 
chain of another residue. In this case, the interaction between Asn96 and Ile80 (Error! Reference 
source not found.a) causes a kink in the α-helix spanning residues Pro89-Lys109 and changes the 
orientation of the Asn96 carbonyl group. This allows the Asn96 carbonyl group to hydrogen-bond 
one of the water molecules in the water chain (Error! Reference source not found.b). 
The sidechain of Lys129 in TbTDH hydrogen-bonds with Asn282 and may have a stabilising role in 
this region of the enzyme, which is located on the exterior, behind the active site (Supplementary 
Figure12).  Lys129 corresponds to Arg180 in the homologous murine TDH (Supplementary Figure 
12).  An R180K variant of this enzyme has been shown to have reduced thermostability and impaired 
recognition of L-threonine , as indicated by reduced catalytic efficiency (He et al., 2015).  Inspection 
of the structure suggests that replacement of arginine with lysine in TbTDH and bacterial TDH 
probably results in relatively fewer interactions with surrounding residues, and thus, a weaker 
stabilising effect. 
3.4. Other features observed in crystallographic models 
A number of molecular species from the storage buffer and from the crystallisation solutions were 
found to co-crystallise with TDH; glycerol, acetate, sulphate and sodium ions were all observed in 
TDH structure models. These molecules occupied various positions, and a few positions were 
occupied in a consistent manner and observed in multiple structures. Most notably, glycerol and 
acetate bound within the L-threonine binding site (Supplementary Figure 13). Glycerol was also 
found to bind to the same regions in different TDH models (Supplementary Figure 14). 
Typically, different TDH dimers in each of the solved structures are separated from other monomers 
by an ordered array of water molecules. However, one direct interaction between two monomers in 
separate dimers was observed in one model (PDB: 5K50). Interestingly, the interaction is formed 
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between residues of the flexible Loop 2 region (Supplementary Figure 15). The interaction does not 
appear to be strong enough to be an important physiological interaction and is likely to be a result of 
the crystallisation process. 
 
3.5. Geometric Simulations 
3.5.1. Noncovalent constraint identification using FIRST 
We have examined the dimeric crystal structures using FIRST, which identifies noncovalent polar and 
hydrophobic interactions and assesses their effect in rigidifying the structure. FIRST identifies a well-
formed network of hydrophobic tethers, hydrogen bonds and salt bridges in the dimer interface 
region, consistent with the PISA analysis. These interactions do not, however, make the dimer into a 
rigid unit; instead, flexibility remains, consistent with the observed differences between the apo, 
holo, and threonine-bound crystal structures. The Loop 1 region appears not to be constrained by 
any noncovalent interactions; this is consistent with the crystallographic observations of flexibility in 
this region. 
 
3.5.2. Low-frequency flexible motion identified using Elnemo and FIRST/FRODA 
We have identified low-frequency mode eigenvectors using coarse-grained elastic networking with 
the Elnemo software, and we have carried out all-atom simulations of flexible motion using the 
FRODA geometric simulation software (incorporated in FIRST) to explore motion biased along these 
low-frequency mode directions. The most intriguing large-scale motion we identify is that along the 
lowest-frequency nontrivial mode of motion (Elnemo's mode 7: modes 1-6 are trivial rigid body 
motions). This motion is predominantly a twisting motion about an axis running perpendicularly 
through the dimer interface, i.e. as if the dimer were being twisted about its long axis. The motion is 
easily permitted by the constraints in the interface region, with large amplitudes of motion (several 
Å RMSD) being achieved in the geometric simulations; the long flexible sidechains which form the 
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inter-dimer interactions easily accommodate the motion. The character of this motion is essentially 
identical for the apo, holo and L-threonine-bound forms. 
This twisting motion appears to account for most of the global differences observed between the 
apo, holo, and L-threonine-bound forms of the dimer. The holo and L-threonine-bound forms can be 
superimposed on the apo form with fitted backbone atom RMSDs of 1.13 Å and 1.58 Å, respectively. 
However, the geometric simulation of motion of the apo form biased along the lowest-frequency 
nontrivial mode generates a conformation which resembles the holo form more closely, with a fitted 
backbone atom RMSD of 0.49 Å, and, shortly thereafter, a conformation which resembles the L-
threonine-bound form, with a fitted backbone atom RMSD of 0.63 Å. These superpositions are 
shown in Error! Reference source not found..  Simulations beginning from the holo and L-threonine-
bound forms (not shown) give consistent results and visit states closely resembling the apo form. 
3.5.3. Random (diffusive) motion in the flexible Loop 1 region 
To assess the freedom of motion in Loop 1, which as noted is not restrained by any identifiable 
noncovalent interaction, we have carried out unbiased geometric simulations of random diffusive 
motion in the protein starting from the apo state. In one such simulation, the residues making up 
Loop 1 were observed to drift from their initial "open" state to a much more "closed" state, as 
shown in in Figure 10. This confirms that the loop has the conformational freedom required to visit 
both open and closed states regardless of the binding of substrate, and is suggestive of a 
conformational-selection mechanism rather than a directly induced-fit mechanism of active site 
closure by Loop 1. 
4. Discussion 
4.1. TbTDH as a GalE-like TDH 
TbTDH is a GalE-like TDH, sharing many features with the enzymes from F. frigidimaris (FfTDH), C. 
necator (CnTDH) and T. volcanium (TvTDH) (Kazuoka et al., 2003; Yoneda et al., 2010; Ueatrongchit & 
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Asano, 2011; Yoneda et al., 2012).  We have shown that TbTDH possesses features that are 
conserved amongst these enzymes, as well as other enzymes within the SDR enzyme superfamily: a 
monomeric length of around 320 residues, a glycine-rich region (GxxGxxG) within the NAD-binding 
domain, a structural motif including lysine and tyrosine (YxxxK) near the active site, and several 
other conserved active site residues (Error! Reference source not found.).  These features contrast 
with TDH in other species, such as E. coli, Pyrococcus horikoshii and Thermococcus kodakarensis, 
which are homotetramers from a different class of enzyme, rather than homodimers, and which 
specifically bind divalent metal cations such as zinc (Johnson et al., 1998; Higashi et al., 2005; 
Bowyer et al., 2009).   
Another distinguishing feature of GalE-like TDHs is the presence of a loop adjacent to the active site 
which is directly followed by a motif represented by the sequence GTTDY (Yoneda et al., 2012).  In 
TbTDH, this ‘flexible Loop 1’ is followed by a similar sequence, GATDY, but it is unclear if this confers 
any structural or functional difference between these and the other known GalE-like TDHs.  
We have provided multiple lines of evidence that TbTDH, like its aforementioned analogues, exists in 
dimeric form in solution.  In SEC studies, we observed a change in elution volumes which suggested 
that TDH and KBL may interact in solution, possibly leading to the dissociation of homodimers and 
the potential formation of a multi-enzyme complex. The formation of a TDH:KBL complex has been 
explored elsewhere (Bowyer et al., 2009; Dale, 1978; Marcus & Dekker, 1993a; Jamil, 2012), but it 
has not been confirmed for a GalE-like TDH and it remains a subject of ongoing investigation for 
TbTDH.  
Overall, the structural characteristics observed place TbTDH in the ‘extended’ category of SDRs 
(eSDR), and thus the enzyme is assigned the identifier SDR14E under the SDR nomenclature initiative 
(Persson et al., 2009). Details of other SDR-type TDH enzymes can be found along with their PDB 
accession codes in Supplementary Table 3. 
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4.2. TbTDH conformational flexibility 
4.2.1. Conformational variability 
Figures 3, 4 and 9 indicate the various regions of flexibility and dynamic behaviour that TbTDH may 
possess in solution.  Comparisons of different X-ray crystallographic structures and the geometric 
simulations show that global motions in the TDH homodimer consist of a combination of hinge and 
shear motions, where the two subunits appear to twist in opposite directions about the dimer 
interface.  These conformational variations are likely to predominate, as exemplified by the fact that 
the models arising from various geometric simulations can be superimposed over crystallographic 
structures of both apo- and holo-TbTDH.  Other important conformational changes may involve 
alterations in the relative positions of the NAD-binding and catalytic domain. 
Recent studies on other dimeric enzymes (Wells et al., 2015, 2014) have shown that low-frequency 
motions can be intimately involved in the opening and closing of enzyme active sites. In the case of 
TbTDH, however, the lowest-frequency motion gives a good description of the global differences 
among the apo/holo/threonine-bound series of structures, but the motion has no particular effect 
on the active site geometry. It is therefore plausible that the different degrees of twisting in the 
different dimer structures represent states from a broad conformational ensemble of flexible 
variation, selected by crystallisation conditions, i.e. the twisting motion may not be directly related 
to the enzyme function. 
The most obvious regions of conformational variability in TbTDH are the flexible Loops 1 and 2.  
Whereas it is unclear whether Loop 2 has any functional role, it appears that Loop 1 may have an 
important role in substrate binding.  We will discuss this in more detail below. 
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4.3. Substrate binding and catalytic Mechanism of Action  
The NADH- and L-threonine-bound structure presented here (Error! Reference source not found.) is 
only accompanied in the literature by one other threonine-bound wild-type TDH structure (Nakano 
et al., 2014). Both structures provide valuable insights into the proposed mechanism of action of 
TDH, in which a hydride is transferred from the β-carbon of L-threonine to the C4 atom of the 
nicotinamide ring of NAD+; both L-threonine and the co-factor are bound in the necessary 
orientation for catalysis.  Furthermore, the nicotinamide ring was bound in a syn conformation, 
meaning that the hydride is transferred to the pro-S position on the C4 carbon.   
The residues of the “catalytic triad” (Winberg et al., 1999; Gani et al., 2008), which have been 
described in alcohol dehydrogenases (ADH) and SDRs in general, have been identified as Thr119, 
Tyr144 and Lys148 in TbTDH.  The residues Thr119 and Tyr144 appear to hydrogen-bond the side 
chain hydroxyl group of L-threonine.  The interatomic distances between the oxygen atoms of the 
relevant groups on L-threonine and Tyr144 also seem to support the hypothesis that Tyr144 acts as a 
base and withdraws a proton from the substrate.  Molecular dynamics simulations in Drosophila 
ADH have demonstrated that this is made possible by the fact that the protonation states of the 
active site tyrosine and lysine residues are coupled (Koumanov et al., 2003; Winberg et al., 1999; 
Gani et al., 2008).  Extrapolating this theory to the TDH mechanism of action, the lysine residue 
(Lys148 in TbTDH) extracts a proton from a hydroxyl group on a NAD ribose group, which in turn 
extracts the proton from the tyrosine residue, thus allowing it to extract the proton from L-
threonine.  In ADH, this proton is then proposed to be transferred to a chain of eight water 
molecules, which relay the proton until it is removed from the interior of the enzyme.  In this way, 
the tyrosine residue is deprotonated again and is able to participate in the catalysis of another 
reaction (Koumanov et al., 2003; Wuxiuer et al., 2012).  The interatomic distances between the 
relevant groups observed in TDH structure models all seem to lend support to this theory.  The pH 
dependence of the protonation state of lysine and tyrosine may also explain why the optimum pH in 
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TbTDH (unpublished research) and other GalE-like TDHs is around pH 8-9 (Green & Elliott, 1964; 
Linstead et al., 1977; Aoyama & Motokawa, 1981; Ray & Ray, 1985; Wagner & Andreesen, 1995; 
Kazuoka et al., 2003; Ueatrongchit & Asano, 2011; Yoneda et al., 2012).  A short chain of water 
molecules close to Lys148 was identified in several of the TbTDH structures obtained here, but a 
complete chain of eight water molecules, which has been shown to be essential for ADH activity 
(Wuxiuer et al., 2012), was not observed.  It is possible that a shorter water chain is sufficient for 
activity in TDH.  Alternatively, it may be that the conformational state of TDH in which this water 
chain is complete has not been captured in any of the crystallographic models to date. 
 
Loops analogous to the flexible Loop 1 identified in TbTDH have been highlighted in TDH from other 
species (Yoneda et al., 2010; Nakano et al., 2014). Indeed, the amino acid sequence corresponding 
to this loop appears to be a conserved feature among GalE-like TDHs.  The studies here provide 
crystallographic evidence of distinct conformations adopted by Loop 1 which are characterised by a 
dramatic shift of approximately 5 Å in distance.  In the X-ray crystallographic structures of TbTDH, 
Loop 1 was observed in the ‘open’ conformation and the ‘closed’ conformation in a number of 
contexts, including in cofactor-bound structures, and structures bound to a cofactor plus L-threonine 
or another ligand.   
Although the data are not conclusive, one can hypothesise that Loop 1 can be in an open or closed 
conformation, regardless of whether a substrate is bound in the L-threonine binding site or not.  It is 
possible that a change to a closed conformation is induced by binding of a ligand to the L-threonine 
binding site, as was observed with L-threonine- and pyruvate-bound structures.  However, one 
structure (PDB: 5K50) shows that binding of L-allo-threonine did not induce a closed conformation.  
The observation that different Loop 1 conformations can be adopted in different subunits of the 
same TDH dimer (as observed in PDB: 5K4U [Supplementary Figure 16]) suggests that the Loop 1 
conformation in each monomer is adopted independently of the conformation in the other subunit.  
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The random walk geometric simulations of TbTDH indicate that the loop may have some 
conformational freedom due to a lack of restraints on this motif.  Alternatively, there may be a 
mechanism whereby the conformation of one subunit affects the conformation in the other subunit.  
He et al. proposed that the residue Arg180 in MmTDH, which corresponds to Lys129 in TbTDH, may 
act as a remote “switch” between the open and closed forms of TDH (He et al., 2015).  Although 
these residues are not located in regions of conformational variability (Figure 3 and Figure 4), Lys 
129 does interact with Asn282, which is in close proximity to the flexible region at residues 255-275.  
Further investigation will be required to understand if Lys129 plays a role in the stability and 
catalysis of TDH from T. brucei. 
Considering the effect that it has on the active site of TDH, it is possible that Loop 1 plays an 
important role in the mechanism of TDH binding to its ligands.  The loop may remain open before 
and after NAD+ binding to accommodate L-threonine, but then close over the active site once L-
threonine is bound. Recently, data from studies of TDH from C. necator have also demonstrated that 
this loop region adopts different conformations in ‘open’ and ‘closed’ structures of TDH.  Using a 
combination of crystallographic data from apo and holo forms of CnTDH, molecular dynamics 
simulations and enzyme kinetics were used to build a hypothesis of ligand binding and structural 
changes in this enzyme. Nakano et al. proposed a model whereby NAD+ binding caused a 
rigidification of flexible regions in the NAD-binding domain, but the flexible loop remained open.  
Then, in the same model L-threonine binding causes Loop 1 to close over the active site, and this 
accounts for the selectivity of the enzyme for L-threonine (Nakano et al., 2014). 
These findings are in some agreement with those presented herein, which suggest that changes in 
the conformation of Loop 1 and the catalytic domain of TbTDH happen in response to L-threonine 
binding.  The findings of Nakano et al. also support the existence of an induced fit mechanism of 
ligand binding for TDH, as Loop 1 seems to form a “lid” over the L-threonine active site, something 
that would prevent L-threonine binding if it happened prior to its encounter with the enzyme.  Some 
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researchers assert that all enzymes that form a lid over their active sites must act by induced fit 
mechanisms (Sullivan & Holyoak, 2008); the findings on TDH structure would seem to illustrate this 
well.  However, some structures presented herein show that TbTDH can adopt a ‘closed’ 
conformation in the absence of L-threonine (e.g.  PDB: 5K4V or PDB: 5K4U; see Table 2).  
Furthermore, rigidity analysis and geometric simulations of apo-TbTDH suggest that Loop 1 has the 
conformational freedom to enter the closed state in the absence of ligands.  Therefore, in the case 
of TbTDH, an induced fit mechanism may occur as part of the wider process of conformational 
selection, which has been proposed as a way in which proteins with variable conformations can 
adopt the necessary state required to carry out a function (Hammes et al., 2009).  Although the 
flexibility of Loop 1 may be linked to the selectivity of TDH for binding and catalysis of L-threonine, 
the possibility that the enzyme may sample several different conformations in solution may allow a 
greater variety of ligands to bind, beyond analogues of the natural substrates.  This could have 
significant implications for drug discovery efforts involving TDH as a target. 
4.4 Relevance of findings to future structure-based drug design 
The TDH studied here is identical to that from HAT-causing T. brucei gambiense and shares high 
sequence similarity with the Chagas disease-causing T. cruzi and animal trypanosomiasis-causing T. 
congolense. Thus, the data presented could be value for human or veterinary trypanosomiasis drug 
discovery efforts.  
We have shown that TbTDH exhibits conformational variability.  However, this does not seem to 
have a significant effect on the relative positions of important substrate binding residues, providing 
a useful basis for the rational design of TDH inhibitors.   In contrast, the flexibility of Loop 1 has a 
profound effect on the nature of the L-threonine binding site, and its conformational variability 
would be an important consideration during the design of an inhibitor targeting that site.  In one 
respect, the closure of Loop 1 is likely to provide greater specificity of TDH for L-threonine or for a 
given inhibitor. However, it restricts access to the active site, which could be a barrier to the binding 
of larger inhibitors or those that target the TDH-L-threonine complex. 
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The NAD binding site consists of a deep cleft, where several hydrophobic and hydrophilic residues 
can be targeted for binding.  The binding pocket is larger than the NAD molecule itself, providing 
pockets and additional residues that could be exploited to increase the affinity of a designed ligand.  
Furthermore, our data show that an inhibitor designed to simultaneously bind within the NAD and L-
threonine binding pockets is feasible and could be useful strategy for achieving high specificity, 
though the presence of Met81 may limit the extent to which the proximity of the two binding sites 
can be used. 
 
4.5 Conclusion 
In this study, the structure of TbTDH has been described in detail, providing insights into the 
dynamic behaviour of the enzyme and how this may relate to its function.  The relationship between 
the enzyme and its natural substrates has been highlighted, and the possible interaction between 
TDH and KBL has been explored.  This new information will contribute to the interpretation of 
further functional data on TDH, which could in turn help to guide drug discovery efforts.  
Furthermore, these findings add to the knowledge-base of the related enzymes of the SDR family. 
Accession numbers 
Coordinates and structure factors for all structures cited herein have been deposited in the Protein 
Data Bank with the following accession numbers: 5L9A; 5LC1; 5K4Q; 5K4T; 5K4V; 5K4U; 5K50; 
5K4W; 5K4Y. 
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Table 1. Details of crystallisation conditions used in the preparation of crystals from which data were collected. Note that all co-crystals were obtained by co-crystallisation. 
 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Crystallisation Conditions          
Conditions 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]) 
0.1 M 
HEPES; 20 
% w/v PEG 
10K; pH 7.5; 
TDH (5.28 x 
10-2mM [2.0 
mg/ml]); 
NAD+ 
(1mM); 
pyruvate 
(30mM) 
0.2M lithium 
sulphate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (6.4 x 
10-2mM 
[2.4mg/ml]); 
KBL (3.8 x 
10-2mM 
[1.8mg/ml]); 
NAD+ 
(0.09mM); 
PLP 
(0.18mM);  
L-Threonine 
(7.33mM) 
0.1M MES; 
0.2M 
ammonium 
sulphate; 
30% w/v 
PEG 5K 
MME; pH 
6.5; 
TDH (9.0 x 
10-2mM 
[3.4mg/ml]);  
L-serine 
(50mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
8.5;  
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
BPOB 
(0.5mM) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(8.5mM); 
quinine 
(2.5mM 
[hydrochlorid
e 
dehydrate]) 
0.1M tri-
sodium 
citrate; 30% 
w/v PEG 4K; 
0.2M 
ammonium 
acetate; pH 
5.6; 
TDH (10.4 x 
10-2mM 
[3.9mg/ml]); 
NAD+ 
(10mM); L-
allo-
threonine 
(30mM) 
0.2M sodium 
acetate; 
0.1M Tris; 
30% w/v 
PEG 4K; pH 
8.5; 
TDH (9.3 x 
10-2mM 
[3.5mg/ml]); 
NADH 
(10mM);  
L-Threonine 
(30mM) 
0.1M tri-
sodium 
citrate; 25% 
w/v PEG 
4K; 0.2M 
ammonium 
acetate; pH 
5.6 
TDH (3.7 x 
10-2mM 
[1.4mg/ml]); 
NAD+ 
(10mM); 
methylglyox
al (8mM) 
Cryoprotectant Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol Glycerol None None 
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Table 2. Details of data collected and structures solved by X-ray crystallography. *Data collection statistics for the outer resolution shell are provided in brackets. †The high R-free values 
of some of the complexes probably stem from the challenges of processing data and refining structures with a unit cell parameter greater than 270 Angstroms. 
 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Data Collection          
Beamline 
ESRF ID23-
2 
ESRF ID29 ESRF DLS I04-1 DLS I04-1 DLS  DLS I04-1 DLS I02 DLS I04-1 
Wavelength (Å) 0.8726 1.07356 0.9334 0.9173 0.9173 0.9173 0.92 0.9795 0.92001 
Space group P1 P21212 P21212 P43212 P21212 P21212 P21212 P21212 P21212 
Unit cell parameters          
a (Å) 46.98 132.03 132.04 91.76 90.40 90.07 133.03 83.45 133.45 
b (Å) 57.72 276.49 276.49 91.76 131.53 133.10 273.06 136.12 278.63 
c (Å) 70.07 55.74 55.74 93.60 55.02 55.61 55.80 55.69 56.27 
α (°) 72.46 90 90 90 90 90 90 90 90 
β (°) 70.38 90 90 90 90 90 90 90 90 
γ (°) 73.20 90 90 90 90 90 90 90 90 
No. of reflections 409937 874324 624537 301645 109277 203173 297998 435135 438691 
No. of unique reflections (used) 109054 117204 93173 23982 32475 61881 91289 67909 193067 
Solvent content (%) 44.20 45.05 46.34 52.83 42.88 43.94 44.98 41.24 46.7 
Matthews coefficient (Å3.Da-1) 2.20 2.24 2.29 2.61 2.15 2.19 2.23 2.09 2.31 
Resolution range (Å)* 
53.82 - 1.45 
(1.53 - 1.45) 
95.48 - 2.10 
(2.21 - 2.10) 
48.14 - 2.30 
(2.42 - 2.30) 
29.54 – 1.91 
(1.96 - 1.91) 
28.23 - 2.20 
(2.32 - 2.20) 
29.29 - 1.79 
(1.89 - 1.79) 
31.09 - 2.26 
(2.34 – 2.26) 
46.32 - 1.72 
(1.76 - 1.72) 
40.12 - 1.77 
(1.80 - 
1.77) 
Multiplicity* 3.8 (2.3) 7.5 (3.3) 6.7 (4.6) 12.6 (10.0) 3.4 (3.0) 3.3 (3.3) 1.9 (1.9) 6.4 (6.6) 6.2 (6.3) 
Completeness (%)*  95.0 (82.1)  97.3 (81.9) 99.2 (95.3) 100.0 (95.2) 96.0 (95.1)  98.0 (97.5) 90.4 (92.5) 99.5 (100.0) 99.8 (99.9) 
Mean I/σ(I) * 10.4 (2.7) 11.4 (3.2) 11.2 (4.4) 33.6 (3.7) 13.4 (3.9) 12.7 (2.8) 5.6 (1.9) 11.0 (2.5) 12.7 (4.1) 
Rmerge (%)* 8.9 (39.8) 14.5 (52.5) 12.0 (27.6) 5.4 (70.9) 6.7 (30.5) 7.4 (46.0) 15.1 (64.6) 9.4 (76.5) 8.6 (41.4) 
Rpim (%)* 5.1 (33.1) 5.5 (26.9) 4.9 (14.2) 1.6 (24.3) 4.0 (19.7) 4.8 (29.9) 15.1 (64.6) 4.0 (32.2) 3.7 (17.9) 
Rmeas (%)* 10.3 (52.2) 15.6 (59.4) 13.0 (31.3) 5.6 (78.7) 7.9 (36.6) 8.8 (55.1) 21.4 (91.4) 10.2 (83.1) 9.4 (45.2) 
Refinement          
Max. resolution (Å) 1.45 2.10 2.3 2.1 2.2 1.9 2.26 1.72 1.77 
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 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Rwork (%) 16.5 18.1 17.5 17.4 16.4 18.6 20.7 15.2 16.1 
Rfree (%) † 22.2 28.7 26.2 24.0 24.1 23.2 28.1 19.8 20.1 
RMS bond lengths (Å) 0.011 0.008 0.0178 0.0245 0.0201 0.0241 0.0128 0.0198 0.0201 
RMS bond angles (°) 2.198 1.837 1.764 2.059 1.826 1.99 1.6492 2.1037 1.9749 
Average B-factor (Å2) 18.68 22.20 21.09 26.769 26.234 22.138 33.76 27.689 19.218 
Ramachandran favoured, % of 
total 
696, 97.6% 1872, 97.0% 
1830, 
96.62% 
309, 96.87% 613, 96.69% 618, 97.48% 
1801, 
95.14% 
622, 97.65% 
1824, 
97.91% 
Ramachandran allowed, % of 
total 
711, 99.7% 1923, 99.6% 61, 3.22% 8, 2.51% 18, 2.84% 14, 2.21% 82, 4.33% 13, 2.04% 33, 1.77% 
Ramachandran outliers, % of 
total 
2, 0.3% 7, 0.4% 3, 0.16% 2, 0.63% 3, 0.47% 2, 0.32% 10, 0.53% 2, 0.31% 6, 0.32% 
Molecules in the asymmetric unit 2 6 6 1 2 2 6 2 6 
Quaternary structure Dimer Dimer Dimer Dimer Dimer Dimer Dimer Dimer Dimer 
Residue range His1-Leu321 His1-Leu321 Pro3-Leu321 His1-Leu321 Pro3-Leu321 Pro3-Leu321 Pro3-Leu321 His1-Leu321 
Met2-
Leu321 
No. protein atoms per monomer 2621 2511 2493 2532 2493 2493 2500.5 2507 2533 
No. water molecules per 
monomer 
651 328 252.3 152 220.5 100.5 73.7 210 241.1 
NAD+ bound? No Yes Yes No Yes Yes Yes Yes (NADH) Yes 
Ligands bound, Mean B-factor - 
NAD, 17.69 
Pyruvate, 
23.07 
NAD, 21.54 
Pyruvate, 
32.95 
NAD, 16.75 
Pyruvate, 
45.43 
NAD, 14.71 
Pyruvate, 
28.07  
NAD, 21.78 
Pyruvate, 
41.96 
NAD, 17.43 
NAD, 21.38 
NAD, 23.70 
NAD, 18.70 
NAD, 15.34 
NAD, 22.09 
NAD, 16.01 
 NAD, 30.90 
NAD, 26.30 
NAD, 15.76 
NAD, 17.58 
NAD, 26.36 
NAD, 20.73 
NAD, 21.75 
NAD, 24.45 
NAD, 24.58 
NAD, 23.92 
L-allo-
threonine, 
39.53 
L-allo-
threonine, 
26.88 
NAD, 22.22 
NAD, 22.68 
L-threonine, 
26.06 
L-threonine, 
30.58 
NAD, 11.34 
NAD, 12.22 
NAD, 12.52 
NAD, 11.02 
NAD, 12.44 
NAD, 12.82 
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 Model 
RCSB PDB ID 5L9A 5LC1 5K4Q 5K4T 5K4V 5K4U 5K50 5K4W 5K4Y 
Pyruvate 
30.47 
Other solvent molecules/ions acetate acetate 
glycerol, 
sulphate 
glycerol 
glycerol, 
acetate, Na+ 
glycerol, 
acetate 
glycerol, 
acetate 
glycerol, Na+ 
glycerol, 
acetate 
Conformation(s) of flexible 
Loop 1 
Open Closed Open Open Closed 
Open and 
Closed 
Open and 
Closed 
Closed Open 
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Figure Legends 
Figure 1. The L-threonine degradation pathway. The enzyme TDH oxidises L-threonine to 2-amino-3-
ketobutyrate (AKB).  KBL then converts AKB to glycine and Ac-CoA.  Alternatively, AKB may undergo 
spontaneous breakdown to aminoacetone and carbon dioxide.  
Figure 2. NAD+-bound TbTDH coloured by secondary structure (gold = α-helix; dark green = β-strand; 
light blue = loop; NAD coloured by heteroatom).  Cartoon representation produced using UCSF 
Chimera. 
Figure 3. Conformational flexibility as indicated by RMSD of Cα positions of the different TbTDH 
structures (PDB: 5K4Q; PDB: 5K4T; PDB: 5K4V; PDB: 5K4U; PDB: 5K50; PDB: 5K4W) when 
superimposed in UCSF Chimera. (a) A ribbon representation of TDH, coloured by the RMSD of α-
carbon positions in each residue. The scale at the bottom of the diagram indicates the colour 
scheme relating to the RMSD measured in Ångstrom. (b) A bar chart showing the RMSD of α-carbons 
per TDH residue. 
Figure 4. A colour representation of the average B-factors of TDH residues, derived from structures 
PDB: 5K4Q, PDB: 5K4T, DB ID: 5K4V, PDB: 5K4U, PDB: 5K50 and PDB: 5K4W. (a) A ribbon diagram of 
TDH coloured by residue-average B-factor (scale in horizontal bar).  The distinct 'closed' position of 
Loop 1 is displayed in red. (b) A chart showing the average B-factor of residues in 'open' TDH 
structures. (c) A chart showing average B-factors of TDH residues in ‘closed’ structures. 
Figure 5. The TDH dimer and its dimerisation interface.  Lines between amino acids indicate Van der 
Waals, polar or ionic interactions. Key residues involved in the interaction include Glu86, Asp90, 
Asp94, Arg101, Lys126, Asp135 and Trp157.  
Figure 6. Binding of NAD+ to TDH in 3D (a) and 2D (b) representations. In (a) hydrogen bonds are 
indicated by red lines; water molecules are depicted as red spheres. In (b) hydrogen bonds are 
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indicated by dotted lines, whilst Van der Waals interactions are represented by green curved lines, 
with the corresponding TDH residues in green text. 
Figure 7. Binding of L-threonine to TDH in 3D (a) and 2D (b) representations, derived from structure 
5K5W. In (a) hydrogen bonds are indicated by red lines, electron density of L-threonine is 
represented by a blue mesh and a water molecule is depicted by a red sphere. In (b) hydrogen bonds 
are indicated by dotted lines, whilst Van der Waals interactions are represented by green curved 
lines, with the corresponding TDH residues in green text. (c) shows a surface representation of 
threonine-bound TDH derived from PDB: 5K4W; the surface of loop 1, which is closed over the active 
site, is coloured red and is semi-transparent.  
Figure 8. Interaction between Asn96 and Ile80 (a), enabling hydrogen bonding of a water atom in a 
larger chain of hydrogen-bonded water molecules (b). Hydrogen bonds are indicated by red lines; 
water molecules are depicted as red spheres.  
Figure 9. Geometric simulations of apo-TbTDH along Elnemo’s mode 7: (a) overlay of multiple 
projections of apo-TbTDH conformations, superposed on holo- (gold) and L-threonine-bound (dark 
red) TbTDH, with arrows indicating direction of the twisting motion; (b) superposition of holo-TbTDH 
(gold) over a projection of the apo form conformation (fitted backbone RMSD = 0.49 Å); (c) 
superposition of L-threonine-bound TbTDH (dark red) over a projection of the apo form 
conformation (backbone fitted RMSD = 0.63 Å).  
Figure 10. Overlays of multiple states of apo-TbTDH during simulations of random diffusive motion.  
The arrow indicates the direction of progressive movement of Loop 1 (in gold) during the simulation.  
States showing extremes of the Loop 1 position are in solid colour, whilst intermediate states are 
translucent. 
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Supplementary Material 
Supplementary Table 1. TDH quaternary structure identified by PISA and confirmed visually. * ΔGdiss = dissociation 
barrier. 
Model Oligomer Accessible surface 
area (Å2) 
Buried surface 
area (Å2) 
ΔGdiss* 
(kcal.mol-
1) 
Stable in 
solution? 
Visual 
confirmation 
Model: 5L9A 
Space group: P1 
Unit cell parameters: 
a=46.98, b=57.72, 
c=70.07; α=72.46°, β= 
70.38°, γ=73.20° 
Molecules in the 
asymmetric unit: 2 
Dimer 25869.5 3161.9 2.5 Yes 
Model: 5LC1 
Space group: P21212 
Unit cell parameters: 
a=132.03, b=276.49, 
c=55.74; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24444.8 5980.5 3.8 Yes 
Dimer 24278.4 6117.1 3.6 Yes 
Dimer 24600.3 5880.2 3.3 Yes 
Model: 5K4Q 
Space group: P21212 
Unit cell parameters: 
a=132.04, b=276.49, 
c=55.74; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24918.1 5470.9 3.3 Yes 
Dimer 24832.7 5449.2 2.6 Yes 
Dimer 24993.7 5428.6 2.3 Yes 
Model: 5K4T 
Space group: P43212 
Unit cell parameters: 
ab=91.76, c=93.60; 
αβγ=90° 
Molecules in the 
asymmetric unit: 1 
Dimer 25239.1 5028.6 3.2 Yes 
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Model Oligomer Accessible surface 
area (Å2) 
Buried surface 
area (Å2) 
ΔGdiss* 
(kcal.mol-
1) 
Stable in 
solution? 
Visual 
confirmation 
Model: 5K4V 
Space group: P21212 
Unit cell parameters: 
a=90.40, b=131.53, 
c=55.02; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24519.8 4880.8 4.4 Yes 
Model: 5K4U 
Space group: P21212 
Unit cell parameters: 
a=133.03,b=273.06, 
c=55.80; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24264.3 7309.4 4.1 Yes 
Model: 5K50 
Space group: P21212 
Unit cell parameters: 
a=133.03, b=273.06, 
c=55.80; αβγ=90° 
Molecules in the 
asymmetric unit: 6 
Dimer 24167.7 4813.6 4.3 Yes 
Dimer 24294.1 4772.0 3.1 Yes 
Dimer 24217.8 4790.1 2.4 Yes 
Model: 5K4W 
Space group: P21212 
Unit cell parameters: 
a=83.45, b=136.12, 
c=55.69; αβγ=90° 
Molecules in the 
asymmetric unit: 2 
Dimer 24587.0 5788.1 0.3 Yes 
Tetramer 46831.2 13919.2 -1.6 Uncertain x (see 
Supplementary 
Figure 12) 
Model: 5K4Y 
Space group: P21212 
Unit cell parameters: 
a=133.45, b=278.63, 
b=56.27; αβγ=90° 
Dimer 24779.8 6050.2 4.5 Yes 
 
24400.6 6351.1 4.1 Yes 
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Model Oligomer Accessible surface 
area (Å2) 
Buried surface 
area (Å2) 
ΔGdiss* 
(kcal.mol-
1) 
Stable in 
solution? 
Visual 
confirmation 
Molecules in the 
asymmetric unit: 6 
 
24521.6 6357.1 3.1 Yes 
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Supplementary Table 2. Samples, elution volumes, predicted molecular weights and corresponding oligomeric forms, as indicated by results of SEC experiments. 
Sample Contents Ve (ml) Ve/V0 Interpolated MW 
(kDa) 
Multiple of MW Suggested 
Oligomeric State 
TDH (1.8 x10-1 mM [6.8mg/ml]) 15 1.79 68.8 1.82 Dimer 
TDH (1.1 x10-1 mM [4mg/ml]) + 10mM NAD+ 15 1.79 68.8 1.82 Dimer 
KBL (4.4 x10-2 mM [2mg/ml]) 14.4 1.71 87.5 1.91 Dimer 
TDH (5.3 x10-2 mM [2mg/ml]) + KBL (4.4 x10-2 mM [2mg/ml]) - 
first peak 
12.5 1.49 187.7 
4.97 (TDH); 4.09 
(KBL) 
Multi-enzyme 
complex 
TDH (5.3 x10-2 mM [2mg/ml]) + KBL (4.4 x10-2 mM [2mg/ml]) - 
second peak 
16.8 1.99 34.0 
0.90 (TDH); 0.74 
(KBL) 
Monomers (TDH 
and/or KBL) 
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Supplementary Table 3. SDR and GalE-like TDH deposited in the Protein Data Bank. 
Organism Amino 
acids 
Quaternary 
structure 
Wild-
type/mutant 
Ligands PDB ID Literature 
reference(s) 
Trypnanosoma 
brucei 
332 Dimer Wild-type - 5L9A This 
manuscript, 
released 22 
JUN 16 
332 Dimer Wild-type NAD; pyruvate 5LC1 This 
manuscript, 
deposited 22 
JUN 16 
332 Dimer Wild-type NAD 5K4Q This 
manuscript, 
released 15 
NOV 17 
332 Dimer Wild-type - 5K4T This 
manuscript, 
released 15 
NOV 17 
332 Dimer Wild-type NAD 5K4V This 
manuscript, 
released 15 
NOV 17 
332 Dimer Wild-type NAD 5K4U This 
manuscript, 
released 15 
NOV 17 
332 Dimer Wild-type NAD,  
L-allo-threonine 
5K50 This 
manuscript, 
released 15 
NOV 17 
332 Dimer Wild-type NAD, L-threonine 5K4W This 
manuscript, 
released 04 
JAN 18 
332 Dimer Wild-type NAD 5K4Y This 
manuscript, 
released 17 
JAN 18 
Flavobacterium 
frigidimaris 
312 Dimer Wild-type NAD; glycerol 2YY7 Febs J 277: 
5124-5132 
(2010) 
Thermoplasma 
volcanium 
 
317 Dimer Wild-type NAD 3A1N J Biol Chem 
287:12966-
12974 (2012) 
317 Dimer Wild-type NAD; pyruvate 3A4V 
317 Dimer Y137F mutant NAD; L-threonine 3A9W 
317 Dimer Y137F mutant NAD; L-3-
Hydroxynorvalin
e 
3AJR 
Mus musculus 373 Dimer Wild-type NAD+ 4YR9 J Struct Biol 
192:510-518 
(2015) 
373 Dimer Wild-type - 4YRA 
373 Dimer R180K mutant NAD 4YRB 
Cupriavidus 
necator 
318 Dimer Wild-type NAD; L-threonine 3WMX J Biol Chem 
289:10445-
10454 (2014) 
318 Dimer Wild-type - 3WMW 
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Supplementary Figure 1. Phylogenetic Tree of TDH from Trypanosoma and other organisms. The lengths of the 
horizontal lines represent the relative genetic distances between the TDH genes from the named organisms.  Genes 
connected to a common branch share a common genetic lineage. The phylogenetic tree was generated using SeaView 4. 
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Supplementary Figure 2. Primary sequence alignment of TDH from Trypanosoma species and other organisms. Each 
residue is represented by the corresponding single-letter code, and residues are coloured according to 8 default families 
of amino acids sharing biochemical characteristics. Sequences of non-aligning residues are represented by a dash. Key 
conserved sequence segments are indicated by an arrow and bold text. The alignment was created using the software 
SeaView 4.  
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Supplementary Figure 3. Protein topology diagram of TDH from T. brucei. From the N-terminus (N) to C-terminus (C), 
alpha helices are lettered from A to Z and beta strands are numbered in ascending order. The secondary structure 
elements are coloured from blue, starting at the N-terminus, through green, yellow and orange to red at the C-terminus. 
This diagram was drawn using Pro-origami software and a monomeric TDH structure (from PDB: 5K4Q).  
 
Supplementary Figure 4. Visualisation of TDH structure (PDB: 5K4W) produced by pdbset, showing all symmetry-related 
molecules in the crystallographic unit cell.  There is one dimer in the asymmetric unit, and four dimers are created by 
crystallographic symmetry. Subunits within the same dimer are coloured differently (blue and gold). 
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Supplementary Figure 5. Silver stain of an SDS-PAGE gel indicating the presence of TDH and KBL in fractions that 
corresponded to peaks on the chromatogram resulting from the size-exclusion chromatography of a mixture of TDH and 
KBL (See Supplementary Table 2). M = molecular weight standards; 1 = fraction at 12-14ml elution (peak at 12.5ml). 2 = 
fraction at 16-18ml(peak at 16.75ml). The protein bands in Lane 1 are light, suggesting that the concentrations of both 
proteins were very low. In Lane 2, which analyses a fraction corresponding to a much larger peak, the bands are less 
distinguishable, due to over-staining in this lane. As the protein concentrations were high, bands corresponding to both 
proteins can still be seen. 
 
Supplementary Figure 6. SDS PAGE analysis of cross-linking experiments with TDH and KBL, on a 9% polyacrylamide gel. 
M = molecular weight standards; 1 = TDH (2.6 x 10-2 mM[1mg/ml]); 2 = TDH (1.3 x 10-2 mM [0.5mg/ml]); 3 = TDH (2.6 x 
10-2 mM [1mg/ml]) non-cross-linked control; 4 = KBL (2.2 x 10-2 mM [1mg/ml]); 5 = KBL (1.1 x 10-2 mM [0.5mg/ml]); 6 = 
KBL (2.2 x 10-2 mM [1mg/ml]) non-cross-linked control; 7 = TDH (2.6 x 10-2 mM [1mg/ml])and KBL (2.2 x 10-2 mM 
[1mg/ml]); 8 = TDH (1.3 x 10-2 mM [0.5mg/ml]) and KBL (1.1 x 10-2 mM [0.5mg/ml]); 9 = BSA control (1.5 x 10-2 mM 
[1mg/ml]). Note that the protein bands of samples exposed to DMS appear higher due to covalent binding with DMS, 
leading to a higher molecular weight. This is also the cause of there being more than one band corresponding to a 
particular oligomer. 
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Supplementary Figure 7. SDS PAGE analysis of cross-linking experiments with TDH (at 2.6 x 10-2 mM [1mg/ml] 
concentration) on a 9% polyacrylamide gel. M = molecular weight standards; 1 = TDH; 2 = TDH and 1mM NAD+; 3 = TDH 
and 10mM NAD+; 4 = TDH, 1mM NAD+ and 30mM L-threonine; 5 = TDH, 10mM NAD+ and 30mM L-threonine; 6 = TDH, 
10mM NAD+ and 15mM L-threonine; 7 = 10mM NAD+ and 30mM L-threonine control. 
 
Supplementary Figure 8. SDS PAGE analysis of cross-linking experiments with KBL (2.2 x 10-2 mM [1mg/ml]) on a 9% 
polyacrylamide gel. M = molecular weight standards; 1 = KBL; 2 = KBL and 1mM PLP; 3 = KBL and 30mM glycine; 4 = KBL 
and 5mM A-CoA; 5 = KBL, 1mM PLP and 30mM glycine; 6 = KBL, 1mM PLP and 5mM A-CoA; 7 = KBL, 1mM PLP, 5mM A-
CoA and 30mM glycine; 8 = KBL, 5mM A-CoA and 30mM glycine. 
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Supplementary Figure 9. SDS PAGE analysis of the pull-down assay to investigate complex formation between TDH and 
KBL. M = molecular weight standards; 1 = original TDH sample; 2 = TDH and thrombin; 3 = TDH with His-tag removed by 
washing the solution through a Ni-NTA column and benzamidine column attached end-to-end; 4 = eluate collected on 
elution of histidine tag from Ni-NTA column; 5 = elution of thrombin (MW approx. 37 kDa) from the benzamidine 
column; 6 = solution flowing through Ni-NTA column as KBL is loaded; 7 = solution flowing through the Ni-NTA column as 
TDH is loaded; 8 = solution flowing through the Ni-NTA column as the column is washed with buffer; 9 = eluate 
containing KBL after applying elution buffer to the column. 
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Supplementary Figure 10. Additional binding pockets in the NAD binding site. Panel a shows a cross-section of TDH, 
focusing on the NAD binding site. The foci of panels b (additional pocket adjacent to C2 atom of adenine) and c 
(additional pocket close to nicotinamide amide) are highlighted in panel A.   
 
 
Supplementary Figure 11. Binding of L-allo-threonine (a, PDB: 5K50) and pyruvate (b, PDB: 5LC1) to TDH in the L-
threonine binding pocket. Hydrogen bonds are indicated by red lines, electron density of bound ligands is represented 
by a blue mesh. 
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Supplementary Figure 12. Equivalent positions of Lys129 and Arg180 in TbTDH (top, PDB: 4YR9) and MmTDH (bottom, 
PDB: 5K4W), respectively. Panels a and b correspond to TbTDH and panels c and d correspond to MmTDH.  Regions 
identified as conformationally variable in this study (for TbTDH) and by He et al. (for MmTDH) are coloured gold in 
panles a and b.  Hydrogen bonds are represented by red lines. 
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Supplementary Figure 13. Binding poses of acetone (a) and glycerol (b) in the L-threonine binding pocket. These 
positions were observed in more than one monomer and/or structure model. 
 
Supplementary Figure 14. Additional binding positions of glycerol on TDH. Glycerol molecules were often found adjacent 
to residues Asp17 (a) and Arg159 (b). 
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Supplementary Figure 15. An interaction between two TDH monomers (PDB: 5K50) at the Loop 2 region (Pro44-Gly50).  
Hydrogen bonds between residues on different subunits are depicted with red lines. 
 
Supplementary Figure 16. Combined ribbon and surface representation of the TDH dimer, determined in crystallographic 
model PDB: 5K4U. In one subunit (green ribbon, left) Loop 1 is in the open conformation. In the second subunit (blue 
ribbon, right) Loop 1 is in the closed conformation. Loop 1 is coloured red in both subunits. 
 
